HIGH-GRADE B-CELL LYMPHOMA
Clinical trials for HIGH-GRADE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy shows promise for tough-to-treat lymphoma
Disease control TerminatedThis study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Lakefront Biotherapeutics NV • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental lymphoma combo trial halted early – only 5 patients enrolled
Disease control TerminatedThis study tested a new combination of drugs (polatuzumab vedotin plus standard chemotherapy) for patients with diffuse large B-cell lymphoma that came back or didn't improve after initial treatment. The trial aimed to see if this mix could shrink tumors better than standard ther…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental lymphoma drug IPH6501 tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope: drug may shield brain from CAR T-Cell therapy side effects
Disease control TerminatedThis study tested whether the drug anakinra could prevent severe brain inflammation (called ICANS) that sometimes happens after CAR T-cell therapy for certain types of lymphoma. The trial involved 23 adults whose lymphoma had returned or not responded to prior treatments. Researc…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New dual-targeting CAR t therapy tested for hard-to-treat lymphoma
Disease control TerminatedThis early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize a…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Radiation after failed CAR t: tiny study halted early
Disease control TerminatedThis pilot study looked at whether radiation therapy could help people with lymphoma that did not respond to CAR T cell therapy. Only 3 participants were enrolled before the study was terminated. The main goal was to check safety and side effects of adding radiation shortly after…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC